Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Inclusion Criteria:

• Informed consent obtained before any study-related activities. Study-relatedactivities are any procedures that are carried out as part of the study, includingactivities to determine suitability for the study.

• Age 18 years or above, and at the legal drinking age according to local requirementsat the time of signing the informed consent.

• Patient-reported history of alcohol overuse for greater than or equal to 5 yearswith an alcohol history of a mean of greater than or equal to 50 grams (male)/40grams (female) pr day for the last year leading up to the time of signing informedconsent.

• Enhanced Liver Fibrosis (ELF) greater than or equal to 9.0 units.

Exclusion Criteria:

• Known or suspected hypersensitivity to study intervention(s) or related products (incl. excipients).

• Previous participation (i.e., signed informed consent) in this study. If exclusioncriteria 7 is met (Vibration Controlled Transient Elastography liver stiffnessmeasurement (LSM) is greater than or equal to 25 Kilopascal (kPa)), a singlerescreening is possible at the investigator's discretion.

• Documented causes of chronic liver disease other than Alcohol-related liver disease (ALD).

• Positive hepatitis B surface antigen (HBsAg), positive human immunodeficiencyvirus-1 (HIV-1) or HIV-2 antibody (Ab), positive hepatitis C virus (HCV) ribonucleicacid (RNA) at screening (V1) or any known presence of HCV RNA or HBsAg within 2years of screening visit 1 (V1).

• Presence or history of ascites more than grade 1, variceal bleeding, hepaticencephalopathy, spontaneous bacterial peritonitis, or liver transplantation atscreening (V1).

• Alcohol hepatitis at randomisation (as defined by National Institute on AlcoholAbuse and Alcoholism (NIAAA)).

• Vibration Controlled Transient Elastography liver stiffness measurement (LSM)greater than or equal to 25 kPa at visit 2 (V2). If participants meet thiscriterion, rescreening is allowed once.

• Presence or history of gastro-oesophageal varices greater than or equal to grade 2*at V2. For participants with LSM greater than or equal to 20 kPa as well as bloodplatelets count less than 150,000 per microliter (μL) of blood anoesophagogastroduodenoscopy performed no more than 52 weeks prior to V2 must beavailable at V2. *Grade 2: varices projecting by one-third of the luminal diameterthat cannot be compressed with air insufflation4.

• Body mass index (BMI) less than or equal to 25 Kilogram Per Square Meter (kg/m^2).

• Female who is pregnant, breast-feeding or intends to become pregnant or is ofchildbearing potential and not using highly effective contraceptive method with lowuser-dependency.